SARS-COV-2 infection in patients with hereditary thrombophilia: Is there a worsening in COVID-19 symptoms?

Marina Cristina Peres 1, Samantha Sanches de Carvalho 1, Anna Carolina Blanco Capassi Santos 1, Thaís Moura Gascón 1, Luiz Vinícius de A Sousa 2, Glaucia Luciano da Veiga 1, Fernando Luiz Affonso Fonseca 1, 3 and Beatriz da Costa Aguiar Alves 1, *

1 Clinical Analysis Laboratory of the FMABC University Center, Santo André, SP, Brazil.
2 Laboratory of Epidemiology and Data Analysis, Centro Universitário FMABC, Santo André, SP, Brazil.
3 Institute of Pharmaceutical Sciences of the Federal University of São Paulo, Diadema, SP, Brazil.
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2022, 21(02), 146–154.
Article DOI: 10.30574/gscbps.2022.21.2.0434
Publication history: 
Received on 04 October 2022; revised on 08 November 2022; accepted on 12 November 2022
 
Abstract: 
Patients with COVID-19 who progressed to a more advanced stage of the disease were observed to develop coagulation disorders. Mutations in genes encoding clotting factors, such as Prothrombin Factor II, Leiden Factor V and MTHFR are associated with the development of thromboembolism. The aim of this study was to determine the prevalence of genetic variants present in these genes in patients with COVID-19, and to associate their presence with disease severity and D-dimer values. 405 patients with different manifestations of COVID-19 were genotyped by qPCR; genotypes were associated with disease severity and D-dimer values. A slightly prevalence of the FVL mutated allele in the group with positive diagnosis was found; also, higher levels of D-dimer in patients who required treatment in intensive care were observed. Individuals with hereditary thrombophilia are at greater risk of developing a thrombolytic event after infection (long-term COVID). Our data show the benefits of performing genetic screening for hereditary thrombophilia in individuals infected with SARS-Cov-2 in order to establish, together with classical laboratory parameters, a risk factor for the development of thrombosis both during the infectious process and for post-COVID and thus avoid a vascular event.
 
Keywords: 
COVID-19; Thrombosis; D-dimer; Genetic variants; Allele prevalence
 
Full text article in PDF: 
 
Copyright information: 
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0

 

Share this